TY  - JOUR
T1  - CArdiovascular device technology and health care cost—reply
AU  - Redberg RF
Y1  - 2011/10/10
N1  - 10.1001/archinternmed.2011.465
JO  - Archives of Internal Medicine
SP  - 1689
EP  - 1689
VL  - 171
IS  - 18
N2  - 
I agree with Dr Dean's statement that the “application of therapy should be based on the evidence.” That is why it is disappointing that he refers to the “life-saving properties” of DESs without offering support for this statement. Indeed, significant mortality benefits have not been seen with DESs.1 The end point used in almost all large, high-quality randomized controlled trials on this subject is a composite outcome, largely driven by decreased need for revascularization.

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2011.465
UR  - http://dx.doi.org/10.1001/archinternmed.2011.465
ER  -